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In Vivo Emergence of High-Level Macrolide Resistance in Streptococcus pneumoniae
following a Single Dose of Azithromycin
Resistance to macrolides in the pneumococcus is generally
by virtue of an efflux pump (encoded by the mefA or mefE
gene) or the presence of a ribosomal methylase (encoded by
the ermB or, rarely, the ermA gene). Horizontal spread of these
genes can occur through inter- and intraspecies recombination
(2). Exposure of the pneumococcus to macrolides can also
lead to the spontaneous generation of resistant mutants in
vivo and in vitro (9); mutations in the 23S rRNA and ribo-
somal proteins L4 and L22 have been described (12). A
recent randomized controlled study clearly demonstrated
the effect of macrolide use on selection of resistant strains of
pharyngeal streptococci (7).
The extent of macrolide use in remote indigenous commu-
nities in Australia is not well documented. Mass azithromycin
treatment campaigns for trachoma eradication have been
linked to selection of macrolide-resistant pneumococcal strains
in the nasopharynx (5, 6) and conjunctiva (3). However, in
populations where macrolide resistance was rare among pneu-
mococci, selection for resistant strains following azithromycin
administration for trachoma control was not evident (1).
As a part of a pneumococcal carriage study of young chil-
dren in remote indigenous communities, we report nasopha-
ryngeal carriage of serial serotype 22F pneumococcal isolates
in a 2.5-month-old indigenous infant. The 22F isolate devel-
oped resistance to azithromycin (while remaining sensitive to
penicillin, tetracycline, chloramphenicol, and cotrimoxazole)
after the infant received a single dose of azithromycin (125 mg)
as routine prophylaxis following a trachoma contact. As shown
in Table 1, the pre- and posttreatment isolates had identical
BOX typing (13) patterns and multilocus sequence types (4).
The mefA/E and ermB genes and mutations in the ribosomal
protein L4 and L22 genes (8, 10–12) were not found in the
isolates. However, the previously described 23S rRNA
A2059G mutation (Escherichia coli numbering) (12) was de-
tected in the posttreatment isolate.
Each subsequent monthly nasal swab from the child over the
following 8 months cultured macrolide-susceptible isolates of
serotype 16F or presumptive nonencapsulated pneumococci.
Five percent of the pneumococcal carriage isolates in the study
were macrolide resistant (erythromycin MIC,2 g/ml). How-
ever, the resistant 22F clone was not detected again despite
intensive surveillance in that community.
The A2059G mutation in pneumococcal passaged mutants
was previously shown to decrease susceptibility to macrolides;
changes at two alleles were associated with an increase in the
azithromycin MIC from 0.02 g/ml to 200 g/ml (12). This
mutation is also believed to slow the replication rate (12) and
would potentially provide a fitness cost.
In another case of de novo development of resistance, a
serotype 3 pneumococcus developed resistance to erythromy-
cin, azithromycin, and quinupristin-dalfopristin (MIC, 2 to 4
g/ml) during azithromycin treatment for pneumococcal pneu-
monia, with a fatal outcome. The mechanism of resistance was
reported to be a mutation in ribosomal protein L22 (9).
Our findings and those of others have important implica-
tions for practice. Strains highly resistant to azithromycin can
arise de novo in a previously sensitive strain, independently
and in the absence of azithromycin resistance in the popula-
tion. Although this may be an unusual occurrence, an impor-
tant consideration during empirical azithromycin treatment for
a pneumococcal infection is that clinical failure may occur even
when the risk of selecting a preexisting azithromycin-resistant
strain is low.
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